Loading
Old drugs like aspirin, statins and beta-blockers show hints of fighting cancer, but no company will pay to prove it. A dedicated public fund should.
The ReDO project (Anticancer Fund) catalogues hundreds of off-patent drugs with anticancer signals; almost none have reached a definitive trial. Public funders have run a few (Add-Aspirin, ALASCCA, MA.32 metformin), and the UK, Belgium and the EU have discussed repurposing frameworks. The proposal is a dedicated international fund (order of $200-300 million a year, from NIHR, NCI, EU and philanthropy) with an independent prioritisation panel, a standing trial network, and a requirement that funded trials be designed to support regulatory label updates and guideline inclusion.
Shares No incentive to repurpose cheap drugs, Funding follows fashion, not burden.
Shares No incentive to repurpose cheap drugs, Funding follows fashion, not burden.
Shares No incentive to repurpose cheap drugs, Funding follows fashion, not burden.
Shares No incentive to repurpose cheap drugs, Funding follows fashion, not burden.
Shares No incentive to repurpose cheap drugs, Funding follows fashion, not burden.